References
- Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence. Worldwide IARC CancerBase No. 5. version 2.0. Lyon, France: IARC Press, 2004
- Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
- American Cancer Society. Cancer Facts & Figures 2008. Atlanta, GA: American Cancer Society, 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf [Last accessed 15 September 2008]
- Meric F. HER-2/neu in the management of invasive breast cancer. J Am Coll Surg 2002;194:488-501
- Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94
- Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17
- Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-55
- Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93
- Bernard-Marty C, Lebrun F, Awada A, et al. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006;66:1577-91
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
- Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
- Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006;11:318-24
- Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-70
- Sherrill B, Amonkar M, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Brit J Cancer 2008;99:711-15
- Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009;117:577-89
- O’Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated ErbB2+ metastatic breast cancer progressing on trastuzumab therapy. Abstract no. 1015. 2008 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL. 30 May-3 June 2008
- Burstein HJ, Blackwell K, Wu Y, et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life (QOL) of patients with trastuzumab-refractory ErbB2+ (ErbB2+) metastatic breast cancer (MBC). Abstract no. 154. 2008 Breast Cancer Symposium of the American Society of Clinical Oncology, Washington, DC. 5-7 September 2008
- Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole vs. letrozole and placebo as first-line therapy for postmenopausal hormone receptor positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46
- Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008;26:5544-52
- Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy Breast quality-of-life instrument. J Clin Oncol 1997;15:974-86
- Eton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57:898-910
- Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986;4:1772-9
- Ulhoa-Cintra A, Greenberg L, Geyer CE. The emerging role of lapatinib in ErbB2-positive breast cancer. Curr Oncol Rep 2008;10:10-17
- Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008;99:711-15
- Revicki DA, Feeny D, Hunt TL, et al. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res 2006;15:411-23